Stammdaten
PTC Therapeutics, Inc., ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entdeckung, Entwicklung und Kommerzialisierung von Medikamenten für Patienten mit seltenen Störungen. Seine Portfolio-Pipeline umfasst kommerzielle Produkte und Produktkandidaten in verschiedenen Entwicklungsstadien, einschließlich klinischer, präklinischer sowie Forschungs- und Entdeckungsstadien, mit Fokus auf die Entwicklung von Behandlungen für mehrere therapeutische Bereiche wie seltene Krankheiten. Das Unternehmen bietet Translarna und Emflaza zur Behandlung der Duchenne-Muskeldystrophie im Europäischen Wirtschaftsraum und den USA an, sowie zur Behandlung von Nonsense-Mutationen Duchenne-Muskeldystrophie in Brasilien und Russland; vermarktet Tegsedi und Waylivra zur Behandlung seltener Krankheiten in Lateinamerika und der Karibik; und vermarktet Evrysdi zur Behandlung spinaler Muskelatrophie bei Erwachsenen und Kindern ab zwei Monaten in Brasilien. Die Splicing-Plattform des Unternehmens umfasst PTC518, das zur Behandlung der Huntington-Krankheit entwickelt wird. PTC Therapeutics, Inc. hat Kooperationen mit F. Hoffman-La Roche Ltd und Hoffman-La Roche Inc., sowie mit der Spinal Muscular Atrophy Foundation zur Förderung der Arzneimittelentdeckung und Entwicklungsforschung in regenerativer Medizin; und Akcea Therapeutics, Inc. zur Kommerzialisierung von Tegsedi und Waylivra zur Behandlung seltener Krankheiten in Lateinamerika und der Karibik. PTC Therapeutics, Inc. wurde 1998 gegründet und hat seinen Sitz in South Plainfield, New Jersey. KI
Unternehmen & Branche
| Name | PTC THERAPEUTICS, INC. |
|---|---|
| Ticker | PTCT |
| CIK | 0001070081 |
| Börse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 69366J200 |
|---|---|
| ISIN | US69366J2006 |
| Typ | Common Stock |
| Marktkapitalisierung | 6,40 Mrd. USD |
| KGV (P/E) | 10,10 |
| Beta | 0,53 |
Sitz & Kontakt
| Sitz (Inkorporation) | DE |
|---|---|
| Geschäftsadresse | 500 WARREN CORPORATE CENTER DRIVE, 07059 WARREN, NJ |
| Telefon | 9082227000 |
| EIN (IRS) | 04-3416587 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
| Frühere Namen | PTC THERAPEUTICS INC (bis 2005) |
Bewertung
| KUV (P/S) | 3,70 vs. 5,24 (2021) ▼ |
|---|---|
| EV/EBITDA | 6,4 |
| FCF-Rendite | 11,0 % vs. -9,9 % (2021) ▲ |
Qualität & Bilanz
| Operative Marge | 50,1 % vs. -69,5 % (2021) ▲ |
|---|---|
| Nettomarge | 39,4 % vs. -97,3 % (2021) ▲ |
| ROIC | 353,0 % vs. -97,6 % (2021) ▲ |
| Nettoverschuldung/EBITDA | -0,6 |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KUV (P/S) | 5,24 | 3,99 | 2,22 | 4,35 | 3,58 | 7,74 | |
| FCF-Rendite | -9,9 % | -13,9 % | -9,0 % | -3,3 % | 11,3 % | -3,5 % | |
| Qualität & Bilanz | |||||||
| Operative Marge | -69,5 % | -64,0 % | -46,9 % | -37,5 % | 50,1 % | -7,1 % | |
| Nettomarge | -97,3 % | -80,0 % | -66,8 % | -45,0 % | 39,4 % | -22,6 % | |
| ROIC | -97,6 % | -156,8 % | – | – | 353,0 % | -87,0 % | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
PTCT
PTC THERAPEUTICS, INC.
Effektiv
Neutral
Handelsvolumen
Hoch
Insider
0,0
Keine Insider-Käufe
Institutionell
32,0
62 neu, 144 erhöht, -883868K $ netto
Aktivist
29,8
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 76.48 | +2.0 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 72.62 | +7.4 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 80.71 | EMA50: 77.57 | |
| MACD-Histogramm | Bärisch | 10 % | -1.275 | Bearisch | |
| RSI(14) | Neutral | 10 % | 45.2 | Neutral (30–70) | |
| Stoch %K(14) | Bullisch | 5 % | 10.2 | Überverkauft | |
| ADX(14)+DI | Neutral | 10 % | 21.5 | +DI: 21.7 / −DI: 20.6 | |
| Z-Score(60) | Neutral | 5 % | 0.47 | In Range | |
| 52W-Position | Neutral | 5 % | 75.0 % | Hoch 89.55 / Tief 43.30 | |
| Bollinger(20,2σ) | Bullisch | 5 % | 16.3 % | Upper 89.80 / Mid 82.76 / Lower 75.72 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.3185 | R²=0.68 / annualisiert +107.2 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-14 | Gravier Pierre | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -3.494 | 80,35 | -280.742,90 | -99,6% | |
| 2026-07-09 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -2.464 | 90,25 | -222.376,00 | -78,9% | |
| 2026-07-09 | Smith Mary L. | Director | Open Market Sale | -10.000 | 90,00 | -900.000,00 | -319,4% | |
| 2026-07-09 | Smith Mary L. | Director | Open Market Sale | -5.834 | 90,00 | -525.060,00 | -186,3% | |
| 2026-07-07 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -11.369 | 89,03 | -1.012.182,07 | -359,2% | |
| 2026-07-07 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -3.956 | 87,17 | -344.844,52 | -122,4% | |
| 2026-07-07 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -9.288 | 89,44 | -830.718,72 | -294,8% | |
| 2026-07-06 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -833 | 84,41 | -70.313,53 | -25,0% | |
| 2026-07-06 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -745 | 86,38 | -64.353,10 | -22,8% | |
| 2026-07-06 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -645 | 85,84 | -55.366,80 | -19,6% | |
| 2026-07-06 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -601 | 86,38 | -51.914,38 | -18,4% | |
| 2026-07-06 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -519 | 85,84 | -44.550,96 | -15,8% | |
| 2026-07-06 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -313 | 83,10 | -26.010,30 | -9,2% | |
| 2026-07-06 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -387 | 83,10 | -32.159,70 | -11,4% | |
| 2026-07-06 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -10.090 | 86,32 | -870.968,80 | -309,1% | |
| 2026-07-06 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -8.786 | 85,35 | -749.885,10 | -266,1% | |
| 2026-07-06 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -2.474 | 87,03 | -215.312,22 | -76,4% | |
| 2026-07-06 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -426 | 85,28 | -36.329,28 | -12,9% | |
| 2026-07-06 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -385 | 86,34 | -33.240,90 | -11,8% | |
| 2026-07-06 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1.036 | 84,41 | -87.448,76 | -31,0% | |
| 2026-06-26 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -412 | 85,23 | -35.114,76 | -12,5% | |
| 2026-06-26 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -7.718 | 85,26 | -658.036,68 | -233,5% | |
| 2026-06-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -582 | 85,24 | -49.609,68 | -17,6% | |
| 2026-06-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -11.337 | 86,51 | -980.763,87 | -348,0% | |
| 2026-06-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -8.522 | 85,26 | -726.585,72 | -257,8% | |
| 2026-06-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -419 | 86,39 | -36.197,41 | -12,8% | |
| 2026-06-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -100 | 87,00 | -8.700,00 | -3,1% | |
| 2026-06-24 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -401 | 85,01 | -34.089,01 | -12,1% | |
| 2026-06-24 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -4.922 | 85,03 | -418.517,66 | -148,5% | |
| 2026-06-22 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -12.130 | 80,61 | -977.799,30 | -347,0% | |
| 2026-06-22 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -11.619 | 81,21 | -943.578,99 | -334,8% | |
| 2026-06-17 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -309 | 79,25 | -24.488,25 | -8,7% | |
| 2026-06-17 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -6.600 | 78,50 | -518.100,00 | -183,8% | |
| 2026-06-17 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1.850 | 79,24 | -146.594,00 | -52,0% | |
| 2026-06-17 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1.703 | 78,50 | -133.685,50 | -47,4% | |
| 2026-06-17 | Utter Christine Marie | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -19.686 | 75,56 | -1.487.474,16 | -527,8% | |
| 2026-06-10 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -17.566 | 75,00 | -1.317.450,00 | -467,5% | |
| 2026-06-10 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -3.711 | 75,00 | -278.325,00 | -98,8% | |
| 2026-05-15 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -2.356 | 72,08 | -169.820,48 | -60,3% | |
| 2026-05-15 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -456 | 72,67 | -33.137,52 | -11,8% | |
| 2026-05-14 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -2.100 | 73,08 | -153.468,00 | -54,5% | |
| 2026-05-14 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -7.221 | 73,08 | -527.710,68 | -187,3% | |
| 2026-05-14 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -2.572 | 72,46 | -186.367,12 | -66,1% | |
| 2026-05-14 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -679 | 73,06 | -49.607,74 | -17,6% | |
| 2026-05-08 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1.900 | 79,31 | -150.689,00 | -53,5% | |
| 2026-05-08 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -840 | 78,23 | -65.713,20 | -23,3% | |
| 2026-05-08 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -600 | 79,28 | -47.568,00 | -16,9% | |
| 2026-05-08 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -200 | 78,00 | -15.600,00 | -5,5% | |
| 2026-04-21 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -2.850 | 70,91 | -202.093,50 | -71,7% | |
| 2026-04-06 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1.443 | 69,75 | -100.649,25 | -35,7% | |
| 2026-04-06 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -822 | 68,91 | -56.644,02 | -20,1% | |
| 2026-04-02 | Golden Lee Scott | Officer, EVP & CHIEF MEDICAL OFFICER | Open Market Sale | -829 | 67,99 | -56.363,71 | -20,0% | |
| 2026-04-01 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -80 | 70,30 | -5.624,00 | -2,0% | |
| 2026-04-01 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -39.393 | 68,89 | -2.713.783,77 | -963,0% | |
| 2026-04-01 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -12.530 | 69,50 | -870.835,00 | -309,0% | |
| 2026-03-12 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -2.662 | 64,08 | -170.580,96 | -60,5% | |
| 2026-03-10 | Okey Stephanie | Director | Open Market Sale | -14.000 | 70,00 | -980.000,00 | -347,7% | |
| 2026-03-10 | Okey Stephanie | Director | Open Market Sale | -1.167 | 70,00 | -81.690,00 | -29,0% | |
| 2026-03-05 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -3.989 | 63,38 | -252.822,82 | -89,7% | |
| 2026-03-05 | Okey Stephanie | Director | Open Market Sale | -6.333 | 63,38 | -401.385,54 | -142,4% | |
| 2026-03-05 | Golden Lee Scott | Officer, EVP & CHIEF MEDICAL OFFICER | Open Market Sale | -10.000 | 63,38 | -633.800,00 | -224,9% | |
| 2026-02-19 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -588 | 68,54 | -40.301,52 | -14,3% | |
| 2026-02-19 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1.629 | 69,82 | -113.736,78 | -40,4% | |
| 2026-02-19 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -590 | 69,82 | -41.193,80 | -14,6% | |
| 2026-02-19 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -212 | 68,54 | -14.530,48 | -5,2% | |
| 2026-02-18 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -65 | 69,36 | -4.508,40 | -1,6% | |
| 2026-02-18 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -7.371 | 69,36 | -511.252,56 | -181,4% | |
| 2026-02-18 | Golden Lee Scott | Officer, EVP & CHIEF MEDICAL OFFICER | Open Market Sale | -2.484 | 69,36 | -172.290,24 | -61,1% | |
| 2026-02-18 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -3.056 | 69,36 | -211.964,16 | -75,2% | |
| 2026-02-18 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -3.019 | 69,36 | -209.397,84 | -74,3% | |
| 2026-02-18 | Gravier Pierre | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -2.992 | 69,36 | -207.525,12 | -73,6% | |
| 2026-02-18 | Utter Christine Marie | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -2.494 | 69,36 | -172.983,84 | -61,4% | |
| 2026-02-18 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -3.081 | 69,36 | -213.698,16 | -75,8% | |
| 2026-02-17 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -2.811 | 69,29 | -194.774,19 | -69,1% | |
| 2026-02-17 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -2 | 70,13 | -140,26 | 0,0% | |
| 2026-01-12 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -1.024 | 78,70 | -80.588,80 | -28,6% | |
| 2026-01-09 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1.521 | 77,46 | -117.816,66 | -41,8% | |
| 2026-01-09 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -107 | 79,52 | -8.508,64 | -3,0% | |
| 2026-01-09 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -1.722 | 77,41 | -133.300,02 | -47,3% | |
| 2026-01-09 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -686 | 78,71 | -53.995,06 | -19,2% | |
| 2026-01-08 | Utter Christine Marie | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -1.034 | 76,45 | -79.049,30 | -28,0% | |
| 2026-01-08 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -2.561 | 76,42 | -195.711,62 | -69,4% | |
| 2026-01-08 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -2.514 | 76,45 | -192.195,30 | -68,2% | |
| 2026-01-08 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -587 | 76,98 | -45.187,26 | -16,0% | |
| 2026-01-08 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -1.454 | 76,45 | -111.158,30 | -39,4% | |
| 2026-01-08 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -881 | 76,45 | -67.352,45 | -23,9% | |
| 2026-01-08 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -59 | 76,45 | -4.510,55 | -1,6% | |
| 2026-01-08 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -2.482 | 76,56 | -190.021,92 | -67,4% | |
| 2026-01-08 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1.286 | 76,45 | -98.314,70 | -34,9% | |
| 2026-01-08 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -265 | 77,07 | -20.423,55 | -7,2% | |
| 2026-01-08 | Golden Lee Scott | Officer, EVP & CHIEF MEDICAL OFFICER | Open Market Sale | -866 | 76,45 | -66.205,70 | -23,5% | |
| 2026-01-07 | Utter Christine Marie | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -1.235 | 77,45 | -95.650,75 | -33,9% | |
| 2026-01-07 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -1.352 | 77,48 | -104.752,96 | -37,2% | |
| 2026-01-07 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -3.016 | 77,48 | -233.679,68 | -82,9% | |
| 2026-01-07 | Golden Lee Scott | Officer, EVP & CHIEF MEDICAL OFFICER | Open Market Sale | -642 | 77,48 | -49.742,16 | -17,7% | |
| 2026-01-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -11 | 78,98 | -868,78 | -0,3% | |
| 2026-01-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -38 | 78,60 | -2.986,80 | -1,1% | |
| 2026-01-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -269 | 77,92 | -20.960,48 | -7,4% | |
| 2026-01-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -471 | 77,10 | -36.314,10 | -12,9% | |
| 2026-01-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -949 | 77,91 | -73.936,59 | -26,2% | |
| 2026-01-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1.503 | 77,48 | -116.452,44 | -41,3% | |
| 2026-01-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1.638 | 77,11 | -126.306,18 | -44,8% | |
| 2026-01-07 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -52 | 77,48 | -4.028,96 | -1,4% | |
| 2026-01-07 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -1.026 | 77,48 | -79.494,48 | -28,2% | |
| 2026-01-06 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1.739 | 76,95 | -133.816,05 | -47,5% | |
| 2026-01-06 | Gravier Pierre | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -2.139 | 76,95 | -164.596,05 | -58,4% | |
| 2026-01-06 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -1.789 | 76,95 | -137.663,55 | -48,8% | |
| 2026-01-06 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -54 | 76,95 | -4.155,30 | -1,5% | |
| 2026-01-06 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -5.149 | 76,95 | -396.215,55 | -140,6% | |
| 2026-01-06 | Golden Lee Scott | Officer, EVP & CHIEF MEDICAL OFFICER | Open Market Sale | -1.340 | 76,95 | -103.113,00 | -36,6% | |
| 2026-01-06 | Utter Christine Marie | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -1.381 | 76,95 | -106.267,95 | -37,7% | |
| 2026-01-06 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -1.279 | 76,95 | -98.419,05 | -34,9% | |
| 2026-01-05 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -108 | 76,79 | -8.293,32 | -2,9% | |
| 2026-01-05 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1.035 | 76,10 | -78.763,50 | -27,9% | |
| 2026-01-05 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1.123 | 74,92 | -84.135,16 | -29,9% | |
| 2026-01-05 | Reeve Emma | Director | Open Market Sale | -734 | 76,00 | -55.784,00 | -19,8% | |
| 2026-01-02 | STEELE GLENN JR MD PHD | Director | Open Market Sale | -12.000 | 76,35 | -916.200,00 | -325,1% | |
| 2025-12-30 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -8.089 | 76,64 | -619.940,96 | -220,0% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -1.500 | 75,77 | -113.655,00 | -40,3% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -3.220 | 78,33 | -252.222,60 | -89,5% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -313 | 77,73 | -24.329,49 | -8,6% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -193 | 75,45 | -14.561,85 | -5,2% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -59 | 78,43 | -4.627,37 | -1,6% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -59 | 78,01 | -4.602,59 | -1,6% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -42 | 77,26 | -3.244,92 | -1,2% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -37 | 75,66 | -2.799,42 | -1,0% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -4.537 | 76,33 | -346.309,21 | -122,9% | |
| 2025-12-19 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -10.548 | 77,55 | -817.997,40 | -290,3% | |
| 2025-12-18 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -120 | 75,02 | -9.002,40 | -3,2% | |
| 2025-12-18 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -2.831 | 75,07 | -212.523,17 | -75,4% | |
| 2025-12-18 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -251 | 75,00 | -18.825,00 | -6,7% | |
| 2025-12-17 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -1.245 | 75,28 | -93.723,60 | -33,3% | |
| 2025-12-17 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -35.261 | 75,44 | -2.660.089,84 | -943,9% | |
| 2025-12-17 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -3.584 | 75,31 | -269.911,04 | -95,8% | |
| 2025-12-17 | Pauwels Eric | Officer, CHIEF BUSINESS OFFICER | Open Market Sale | -100 | 76,00 | -7.600,00 | -2,7% | |
| 2025-12-03 | Reeve Emma | Director | Open Market Sale | -733 | 78,62 | -57.628,46 | -20,4% | |
| 2025-12-02 | Klein Matthew B. | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -3.428 | 79,07 | -271.051,96 | -96,2% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -3.095 | 85,15 | -263.539,25 | -93,5% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -21.844 | 83,33 | -1.820.260,52 | -645,9% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -13.514 | 82,55 | -1.115.580,70 | -395,9% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -9.171 | 84,42 | -774.215,82 | -274,7% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -4.834 | 83,39 | -403.107,26 | -143,0% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -3.744 | 82,61 | -309.291,84 | -109,7% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -3.663 | 83,41 | -305.530,83 | -108,4% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -2.790 | 82,82 | -231.067,80 | -82,0% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -2.621 | 84,54 | -221.579,34 | -78,6% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -1.757 | 84,56 | -148.571,92 | -52,7% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -990 | 83,44 | -82.605,60 | -29,3% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -911 | 82,63 | -75.275,93 | -26,7% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -862 | 83,35 | -71.847,70 | -25,5% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -689 | 82,63 | -56.932,07 | -20,2% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -574 | 84,67 | -48.600,58 | -17,2% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -289 | 84,61 | -24.452,29 | -8,7% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -200 | 85,37 | -17.074,00 | -6,1% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -200 | 85,34 | -17.068,00 | -6,1% | |
| 2025-11-25 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -180 | 85,17 | -15.330,60 | -5,4% | |
| 2025-11-25 | Jacobson Allan Steven | Director | Open Market Sale | -3.502 | 83,38 | -291.996,76 | -103,6% | |
| 2025-11-25 | Jacobson Allan Steven | Director | Open Market Sale | -2.510 | 83,93 | -210.664,30 | -74,8% | |
| 2025-11-25 | Jacobson Allan Steven | Director | Open Market Sale | -2.460 | 82,58 | -203.146,80 | -72,1% | |
| 2025-11-25 | Jacobson Allan Steven | Director | Open Market Sale | -2.264 | 82,63 | -187.074,32 | -66,4% | |
| 2025-11-25 | Jacobson Allan Steven | Director | Open Market Sale | -1.238 | 84,47 | -104.573,86 | -37,1% | |
| 2025-11-25 | Jacobson Allan Steven | Director | Open Market Sale | -1.125 | 84,45 | -95.006,25 | -33,7% | |
| 2025-11-25 | Jacobson Allan Steven | Director | Open Market Sale | -700 | 85,32 | -59.724,00 | -21,2% | |
| 2025-11-25 | Jacobson Allan Steven | Director | Open Market Sale | -400 | 85,24 | -34.096,00 | -12,1% | |
| 2025-11-24 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -21.206 | 80,19 | -1.700.509,14 | -603,4% | |
| 2025-11-24 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -1.650 | 80,14 | -132.231,00 | -46,9% | |
| 2025-11-24 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -1.900 | 80,14 | -152.266,00 | -54,0% | |
| 2025-11-24 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -4.715 | 80,15 | -377.907,25 | -134,1% | |
| 2025-11-24 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -6.101 | 80,17 | -489.117,17 | -173,6% | |
| 2025-11-24 | Jacobson Allan Steven | Director | Open Market Sale | -6.100 | 80,15 | -488.915,00 | -173,5% | |
| 2025-11-24 | Jacobson Allan Steven | Director | Open Market Sale | -5.701 | 80,13 | -456.821,13 | -162,1% | |
| 2025-11-21 | Reeve Emma | Director | Open Market Sale | -10.000 | 79,50 | -795.000,00 | -282,1% | |
| 2025-11-17 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1.843 | 75,64 | -139.404,52 | -49,5% | |
| 2025-11-17 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -777 | 76,53 | -59.463,81 | -21,1% | |
| 2025-11-17 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -192 | 77,18 | -14.818,56 | -5,3% | |
| 2025-11-12 | Reeve Emma | Director | Open Market Sale | -7.333 | 74,50 | -546.308,50 | -193,9% | |
| 2025-10-30 | Reeve Emma | Director | Open Market Sale | -12.000 | 69,50 | -834.000,00 | -295,9% | |
| 2025-10-30 | Reeve Emma | Director | Open Market Sale | -3.666 | 69,50 | -254.787,00 | -90,4% | |
| 2025-10-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -312 | 64,97 | -20.270,64 | -7,2% | |
| 2025-10-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1.757 | 62,89 | -110.497,73 | -39,2% | |
| 2025-10-07 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -1.306 | 63,80 | -83.322,80 | -29,6% | |
| 2025-10-06 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -2.266 | 65,07 | -147.448,62 | -52,3% | |
| 2025-10-03 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -4.276 | 67,15 | -287.133,40 | -101,9% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -4.591 | 66,09 | -303.419,19 | -107,7% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -4.037 | 66,10 | -266.845,70 | -94,7% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -3.149 | 66,11 | -208.180,39 | -73,9% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -3.028 | 65,09 | -197.092,52 | -69,9% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -2.729 | 65,05 | -177.521,45 | -63,0% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -2.381 | 66,87 | -159.217,47 | -56,5% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -2.163 | 65,02 | -140.638,26 | -49,9% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -1.884 | 66,89 | -126.020,76 | -44,7% | |
| 2025-10-03 | Reeve Emma | Director | Open Market Sale | -1.600 | 66,93 | -107.088,00 | -38,0% | |
| 2025-10-03 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -23.863 | 66,45 | -1.585.696,35 | -562,7% | |
| 2025-10-03 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -23.419 | 65,45 | -1.532.773,55 | -543,9% | |
| 2025-10-03 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -1.760 | 66,56 | -117.145,60 | -41,6% | |
| 2025-10-03 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -1.609 | 65,46 | -105.325,14 | -37,4% | |
| 2025-10-03 | Almstead Neil Gregory | Officer, CHIEF TECHNICAL OPS OFFICER | Open Market Sale | -73 | 67,16 | -4.902,68 | -1,7% | |
| 2025-10-03 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -7.400 | 66,44 | -491.656,00 | -174,5% | |
| 2025-10-03 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -6.124 | 65,47 | -400.938,28 | -142,3% | |
| 2025-10-03 | Boulding Mark Elliott | Officer, EXEC. VP AND CLO | Open Market Sale | -3.100 | 64,43 | -199.733,00 | -70,9% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 1693 von typischerweise 8373 Fonds (20 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 17.773.717 | 0 | 17.773.717 | 888.616.380 | Neu | +100,0% | |
| RTW INVESTMENTS, LP | 7.746.415 | 0 | 7.746.415 | 527.763.254 | Neu | +100,0% | |
| Janus Henderson Group Ltd. | 7.193.433 | 0 | 7.193.433 | 489.997.100 | Neu | +100,0% | |
| STATE STREET CORP | 4.346.519 | 0 | 4.346.519 | 296.128.339 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 3.942.610 | 0 | 3.942.610 | 268.610.018 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.676.256 | 0 | 3.676.256 | 250.463.321 | Neu | +100,0% | |
| TORONTO DOMINION BANK | 3.025.963 | 0 | 3.025.963 | 206.158.859 | Neu | +100,0% | |
| ARMISTICE CAPITAL, LLC | 2.464.449 | 0 | 2.464.449 | 167.902.910 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 62.121.388 | 0 | 62.121.388 | 157.797.019 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 2.209.954 | 0 | 2.209.954 | 150.589.658 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 1.886.841 | 0 | 1.886.841 | 128.550.476 | Neu | +100,0% | |
| Hood River Capital Management LLC | 1.664.559 | 0 | 1.664.559 | 113.406.405 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 1.640.381 | 0 | 1.640.381 | 111.759.157 | Neu | +100,0% | |
| FMR LLC | 4.530.362 | 0 | 4.530.362 | 108.121.865 | Neu | +100,0% | |
| TANG CAPITAL MANAGEMENT LLC | 1.500.000 | 0 | 1.500.000 | 102.195.000 | Neu | +100,0% | |
| UBS Group AG | 1.364.768 | 0 | 1.364.768 | 92.981.644 | Neu | +100,0% | |
| Jefferies Financial Group Inc. | 1.354.459 | 0 | 1.354.459 | 92.279.292 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 1.183.720 | 0 | 1.183.720 | 80.063.048 | Neu | +100,0% | |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1.015.772 | 0 | 1.015.772 | 69.204.546 | Neu | +100,0% | |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 49.839.000 | 0 | 49.839.000 | 66.759.138 | Neu | +100,0% | |
| Palo Alto Investors LP | 921.607 | 0 | 921.607 | 62.789.085 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 920.476 | 0 | 920.476 | 62.712.030 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 890.715 | 0 | 890.715 | 60.674.282 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 827.631 | 0 | 827.631 | 56.386.500 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 806.276 | 0 | 806.276 | 54.931.584 | Neu | +100,0% | |
| Woodline Partners LP | 744.988 | 0 | 744.988 | 50.756.032 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 731.642 | 0 | 731.642 | 49.846.769 | Neu | +100,0% | |
| JUPITER ASSET MANAGEMENT LTD | 711.457 | 0 | 711.457 | 48.471.565 | Neu | +100,0% | |
| MORGAN STANLEY | 674.134 | 0 | 674.134 | 45.928.802 | Neu | +100,0% | |
| Nuveen, LLC | 667.019 | 0 | 667.019 | 45.444.004 | Neu | +100,0% | |
| Boston Partners | 647.482 | 0 | 647.482 | 44.112.149 | Neu | +100,0% | |
| CAPSTONE INVESTMENT ADVISORS, LLC | 31.200.000 | 0 | 31.200.000 | 41.632.500 | Neu | +100,0% | |
| Ensign Peak Advisors, Inc | 582.318 | 0 | 582.318 | 39.673.325 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 533.300 | 0 | 533.300 | 36.333.729 | Neu | +100,0% | |
| PRINCIPAL FINANCIAL GROUP INC | 515.001 | 0 | 515.001 | 35.087.018 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 513.823 | 0 | 513.823 | 35.006.761 | Neu | +100,0% | |
| LOOMIS SAYLES & CO L P | 493.603 | 0 | 493.603 | 33.629.173 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 460.638 | 0 | 460.638 | 31.383.267 | Neu | +100,0% | |
| BALYASNY ASSET MANAGEMENT L.P. | 460.564 | 0 | 460.564 | 31.378.225 | Neu | +100,0% | |
| Sculptor Capital LP | 22.020.000 | 0 | 22.020.000 | 29.408.481 | Neu | +100,0% | |
| Parkman Healthcare Partners LLC | 431.364 | 0 | 431.364 | 29.388.829 | Neu | +100,0% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 425.240 | 0 | 425.240 | 28.971.601 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 413.499 | 0 | 413.499 | 28.171.687 | Neu | +100,0% | |
| Rockefeller Capital Management L.P. | 384.672 | 0 | 384.672 | 26.207.703 | Neu | +100,0% | |
| Defilade Capital Management, L.P. | 376.165 | 0 | 376.165 | 25.628.121 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 362.938 | 0 | 362.938 | 24.726.966 | Neu | +100,0% | |
| DeepCurrents Investment Group LLC | 18.401.000 | 0 | 18.401.000 | 24.550.431 | Neu | +100,0% | |
| LINDEN ADVISORS LP | 18.227.000 | 0 | 18.227.000 | 24.337.827 | Neu | +100,0% | |
| PANAGORA ASSET MANAGEMENT INC | 351.370 | 0 | 351.370 | 23.938.838 | Neu | +100,0% | |
| MACKENZIE FINANCIAL CORP | 345.683 | 0 | 345.683 | 23.551.383 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 1693 von typischerweise 8373 Fonds (20 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Louisiana State Employees Retirement System | 36.400 | 35.600 | +2,2% | 2.969.148 | 17,46 | 100 % | 3 Q |
| QRG CAPITAL MANAGEMENT, INC. | 24.989 | 26.023 | -4,0% | 2.038.328 | 11,99 | 100 % | 4 Q |
| YOUSIF CAPITAL MANAGEMENT, LLC | 22.524 | 22.144 | +1,7% | 1.837.283 | 10,81 | 26 % | 3 Q |
| COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS | 19.670 | 19.855 | -0,9% | 1.604.482 | 9,44 | 100 % | 3 Q |
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Management | 15.916 | 13.851 | +14,9% | 1.298.269 | 7,64 | 96 % | 4 Q |
| Envestnet Portfolio Solutions, Inc. | 13.730 | 13.493 | +1,8% | 1.119.956 | 6,59 | 100 % | 3 Q |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 12.417 | 11.127 | +11,6% | 1.053.623 | 6,20 | 4 % | 6 Q |
| FIRST CITIZENS BANK & TRUST CO | 12.595 | 12.581 | +0,1% | 1.027.374 | 6,04 | 100 % | 2 Q |
| JUNCTURE WEALTH STRATEGIES, LLC | 10.577 | 5.148 | +105,5% | 862.799 | 5,07 | 100 % | 4 Q |
| Assenagon Asset Management S.A. | 6.899 | 61.397 | -88,8% | 562.751 | 3,31 | 100 % | 17 Q |
| PSP Research LLC | 6.000 | 6.000 | 0,0% | 489.420 | 2,88 | 0 % | 3 Q |
| Robeco Institutional Asset Management B.V. | 5.938 | 6.252 | -5,0% | 484.363 | 2,85 | 91 % | 5 Q |
| Diversified Trust Co | 5.434 | 18.557 | -70,7% | 443.251 | 2,61 | 0 % | 17 Q |
| Avior Wealth Management, LLC | 3.780 | 0 | +100,0% | 308.335 | 1,81 | 0 % | 2 Q |
| LANARK FINANCIAL, INC. | 2.803 | 0 | +100,0% | 228.640 | 1,34 | 100 % | 1 Q |
| Crossmark Global Holdings, Inc. | 2.658 | 0 | +100,0% | 216.813 | 1,28 | 100 % | 1 Q |
| GAMMA Investing LLC | 1.453 | 919 | +58,1% | 118.521 | 0,70 | 100 % | 11 Q |
| HARBOR INVESTMENT ADVISORY, LLC | 987 | 0 | +100,0% | 80.510 | 0,47 | 100 % | 6 Q |
| IFP Advisors, Inc | 788 | 1.322 | -40,4% | 64.277 | 0,38 | 100 % | 7 Q |
| Farther Finance Advisors, LLC | 693 | 551 | +25,8% | 56.528 | 0,33 | 0 % | 15 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 46 | 0,3 | 19 |
| 31.03.2026 | ✓ | 355 | 356,6 | 7.472 |
| 31.12.2025 | ✓ | 354 | 345,2 | 7.346 |
| 30.09.2025 | ✓ | 302 | 364,3 | 5.407 |
| 30.06.2025 | ✓ | 287 | 356,5 | 4.093 |
| 31.03.2025 | ✓ | 262 | 373,1 | 4.452 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| Qube Research & Technologies Ltd | 513.823 | 35.006.761 |
| LOOMIS SAYLES & CO L P | 493.603 | 33.629.173 |
| BALYASNY ASSET MANAGEMENT L.P. | 460.564 | 31.378.225 |
| Defilade Capital Management, L.P. | 376.165 | 25.628.121 |
| Schonfeld Strategic Advisors LLC | 318.405 | 21.692.931 |
| Blue Sparrow, LLC /DE | 190.600 | 12.985.578 |
| CAPITAL FUND MANAGEMENT S.A. | 121.286 | 8.263.215 |
| CenterBook Partners LP | 56.813 | 3.870.670 |
| GROUP ONE TRADING LLC | 52.713 | 3.591.337 |
| MOORE CAPITAL MANAGEMENT, LP | 44.694 | 3.045.002 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| CAPSTONE INVESTMENT ADVISORS, LLC | 31.200.000 | 6.200.000 | +24.8 % | 41.632.500 |
| LORD, ABBETT & CO. LLC | 4.672.121 | 4.045.015 | +645.0 % | 47.442 |
| Janus Henderson Group Ltd. | 7.193.433 | 2.342.101 | +48.3 % | 489.997.100 |
| BlackRock, Inc. | 17.773.717 | 1.394.652 | +8.5 % | 888.616.380 |
| Hood River Capital Management LLC | 1.664.559 | 661.484 | +65.9 % | 113.406.405 |
| BANK OF AMERICA CORP /DE/ | 1.886.841 | 455.284 | +31.8 % | 128.550.476 |
| UBS Group AG | 1.364.768 | 400.110 | +41.5 % | 92.981.644 |
| JUPITER ASSET MANAGEMENT LTD | 711.457 | 350.298 | +97.0 % | 48.471.565 |
| Ensign Peak Advisors, Inc | 582.318 | 301.746 | +107.5 % | 39.673.325 |
| Parkman Healthcare Partners LLC | 431.364 | 271.185 | +169.3 % | 29.388.829 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| WHITEBOX ADVISORS LLC | 13.274.000 | -4.226.000 | -24.1 % | 17.662.716 |
| CSS LLC/IL | 2.883.000 | -3.117.000 | -52.0 % | 3.843.581 |
| LINDEN ADVISORS LP | 18.227.000 | -1.752.000 | -8.8 % | 24.337.827 |
| DeepCurrents Investment Group LLC | 18.401.000 | -1.500.000 | -7.5 % | 24.550.431 |
| TORONTO DOMINION BANK | 3.025.963 | -1.112.252 | -26.9 % | 206.158.859 |
| LAZARD ASSET MANAGEMENT LLC | 15.903.988 | -923.212 | -5.5 % | 1.982.434 |
| CITADEL ADVISORS LLC | 385.199 | -769.256 | -66.6 % | 26.243.608 |
| ARMISTICE CAPITAL, LLC | 2.074.449 | -727.420 | -26.0 % | 141.332.210 |
| BNP Paribas Asset Management Holding S.A. | 311.810 | -335.775 | -51.9 % | 21.243.615 |
| Jefferies Financial Group Inc. | 1.354.459 | -304.022 | -18.3 % | 92.279.292 |
Zusätzlich aktuell von 199 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 15.05.2026 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 8,70 % | 7.193.433 | +2,70 pp | |
| 15.05.2026 | The Toronto-Dominion Bank | Passiv (13G/A) | 3,70 % | 3.025.945 | -1,50 pp | |
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 5,17 % | 4.284.448 | Neu | |
| 29.04.2026 | Vanguard Portfolio Management | Passiv (13G) | 5,88 % | 4.871.329 | Neu | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -10,43 pp | |
| 17.02.2026 | JANUS HENDERSON GROUP PLC | Passiv (13G) | 6,00 % | 4.851.332 | Neu | |
| 13.02.2026 | The Toronto-Dominion Bank | Passiv (13G) | 5,20 % | 4.138.215 | Neu | |
| 10.02.2026 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 4,80 % | 3.867.380 | -1,40 pp | |
| 09.02.2026 | STATE STREET CORPORATION | Passiv (13G) | 5,20 % | 4.206.126 | +1,40 pp | |
| 04.12.2025 | BlackRock, Inc. | Passiv (13G/A) | 14,80 % | 11.904.696 | +6,80 pp | |
| 14.11.2025 | Armistice Capital, LLC (+1) | Passiv (13G/A) | 4,08 % | 3.277.272 | -1,88 pp | |
| 30.10.2025 | The Vanguard Group | Passiv (13G/A) | 10,43 % | 8.288.999 | -1,23 pp | |
| 14.08.2025 | Armistice Capital, LLC (+1) | Passiv (13G/A) | 5,96 % | 4.735.464 | -0,90 pp | |
| 15.05.2025 | Armistice Capital, LLC (+1) | Passiv (13G/A) | 6,86 % | 5.434.843 | -1,41 pp | |
| 17.04.2025 | BlackRock, Inc. | Passiv (13G/A) | 8,00 % | 6.274.384 | Neu | |
| 14.02.2025 | Camber Capital Management LP (+1) | Passiv (13G/A) | 4,15 % | 3.200.000 | Neu | |
| 14.02.2025 | Armistice Capital, LLC (+1) | Passiv (13G/A) | 8,27 % | 6.378.000 | -1,13 pp | |
| 10.02.2025 | Wellington Management Company LLP | Passiv (13G/A) | 6,10 % | 4.787.123 | -3,96 pp | |
| 10.02.2025 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 6,20 % | 4.787.123 | -4,06 pp | |
| 14.11.2024 | Armistice Capital, LLC (+1) | Passiv (13G/A) | 9,40 % | 7.234.898 | +0,30 pp | |
| 08.11.2024 | Wellington Management Company LLP | Passiv (13G/A) | 10,06 % | 7.739.181 | -2,70 pp | |
| 08.11.2024 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 10,26 % | 7.892.799 | -2,75 pp | |
| 18.10.2024 | STATE STREET CORPORATION | Passiv (13G/A) | 3,80 % | 2.899.040 | Neu | |
| 14.02.2024 | Armistice Capital, LLC (+1) | Passiv (13G) | 9,10 % | 6.864.000 | Neu | |
| 14.02.2024 | Roderick Wong, M.D. (+1) | Passiv (13G/A) | 9,80 % | 7.423.970 | Neu | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 11,66 % | 8.800.843 | +1,45 pp | |
| 08.02.2024 | Wellington Management Company LLP | Passiv (13G/A) | 12,76 % | 9.632.252 | +2,81 pp | |
| 08.02.2024 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 13,01 % | 9.816.603 | +2,67 pp | |
| 24.01.2024 | : STATE STREET CORPORATION | Passiv (13G/A) | 6,14 % | 0 | Neu | |
| 08.01.2024 | . BlackRock, Inc. | Passiv (13G/A) | 10,20 % | 7.668.871 | +1,00 pp | |
| 30.10.2023 | Camber Capital (+1) | Passiv (13G) | 5,31 % | 4.000.000 | Neu | |
| 14.02.2023 | RTW Investments, LP (+1) | Passiv (13G/A) | 7,70 % | 5.615.387 | +0,20 pp | |
| 09.02.2023 | Janus Henderson Group plc | Passiv (13G/A) | 2,80 % | 2.027.142 | -2,70 pp | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 10,21 % | 7.339.520 | +0,14 pp | |
| 06.02.2023 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 10,34 % | 7.430.907 | -1,20 pp | |
| 06.02.2023 | Wellington Management Company LLP | Passiv (13G/A) | 9,95 % | 7.149.540 | -1,34 pp | |
| 01.02.2023 | Franklin Resources, Inc. (+2) | Passiv (13G/A) | 4,80 % | 3.489.687 | -2,10 pp | |
| 24.01.2023 | . BlackRock, Inc. | Passiv (13G/A) | 9,20 % | 6.640.854 | +0,20 pp | |
| 11.07.2022 | The Vanguard Group | Passiv (13G/A) | 10,07 % | 7.183.692 | +0,33 pp | |
| 14.02.2022 | RTW Investments, LP (+1) | Passiv (13G/A) | 7,50 % | 5.293.966 | Neu |
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | – | -2.809.000 $ | -0,03 $ | 2.869.104.000 $ | -180.465.000 $ |
| 2025-12-31 | 10-K | – | 682.644.000 $ | 7,78 $ | 2.898.767.000 $ | -205.313.000 $ |
| 2025-09-30 | 10-Q | – | 15.896.000 $ | 0,20 $ | 2.643.700.000 $ | -155.758.000 $ |
| 2025-07-31 | 10-K | – | – | – | – | – |
| 2025-07-31 | 10-Q | – | – | – | – | – |
| 2025-06-30 | 10-Q | – | -64.849.000 $ | -0,83 $ | 2.634.155.000 $ | -206.546.000 $ |
| 2025-03-31 | 10-Q | – | 866.562.000 $ | 10,04 $ | 2.655.387.000 $ | -185.760.000 $ |
| 2024-12-31 | 10-K | – | -363.295.000 $ | -4,73 $ | 1.705.024.000 $ | -1.098.071.000 $ |
| 2024-09-30 | 10-Q | – | -106.654.000 $ | -1,39 $ | 1.842.236.000 $ | -1.054.352.000 $ |
| 2024-06-30 | 10-Q | – | -99.179.000 $ | -1,29 $ | 1.916.355.000 $ | -980.181.000 $ |
| 2024-03-31 | 10-Q | – | -91.576.000 $ | -1,20 $ | 1.789.629.000 $ | -893.916.000 $ |
| 2023-12-31 | 10-K | – | -626.604.000 $ | -8,37 $ | 1.895.698.000 $ | -818.555.000 $ |
| 2023-09-30 | 10-Q | – | -132.970.000 $ | -1,76 $ | 1.259.885.000 $ | -670.810.000 $ |
| 2023-06-30 | 10-Q | – | -198.883.000 $ | -2,66 $ | 1.338.124.000 $ | -579.268.000 $ |
| 2023-03-31 | 10-Q | – | -138.959.000 $ | -1,88 $ | 1.608.839.000 $ | -457.561.000 $ |
| 2022-12-31 | 10-K | – | -559.017.000 $ | -7,79 $ | 1.705.619.000 $ | -347.086.000 $ |
| 2022-09-30 | 10-Q | – | -109.315.000 $ | -1,53 $ | 1.576.398.000 $ | -226.904.000 $ |
| 2022-06-30 | 10-Q | – | -152.087.000 $ | -2,13 $ | 1.804.057.000 $ | -182.218.000 $ |
| 2022-03-31 | 10-Q | – | -126.726.000 $ | -1,78 $ | 1.799.591.000 $ | -90.581.000 $ |
| 2021-12-31 | 10-K | – | -523.901.000 $ | -7,43 $ | 1.938.056.000 $ | 1.438.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Collaboration And License Revenue | 998,4 Mio. | – | – | – | – | 43,1 % | Neu | |
| Product | 586,7 Mio. | 601,0 Mio. | 661,2 Mio. | 535,2 Mio. | 428,9 Mio. | 25,3 % | -2,4% | |
| Royalty | 244,2 Mio. | 203,9 Mio. | 168,9 Mio. | 113,5 Mio. | 54,6 Mio. | 10,5 % | +19,8% | |
| Translarna 1 | 235,3 Mio. | – | – | – | – | 10,2 % | Neu | |
| Emflaza | 146,4 Mio. | – | – | – | – | 6,3 % | Neu | |
| Sephience | 111,2 Mio. | – | – | – | – | 4,8 % | Neu | |
| Upstaza And Kebilidi | 56,6 Mio. | – | – | – | – | 2,4 % | Neu | |
| Other Products | 37,3 Mio. | – | – | – | – | 1,6 % | Neu | |
| Translarna | -98.629.000 | – | – | – | – | -4,3 % | Neu | |
| Manufacturing | – | 1,7 Mio. | 7,7 Mio. | – | – | – | – | |
| Collaboration Revenue | – | 304.000 | 100,0 Mio. | – | – | – | – | |
| Grant And Collaboration | – | – | – | 50,1 Mio. | 55,0 Mio. | – | – |
Regionen
| Region | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| US | 252,2 Mio. | 413,0 Mio. | 531,7 Mio. | 498,6 Mio. | 297,0 Mio. | 30,7 % | -38,9% | |
| Non Us | 235,9 Mio. | 393,7 Mio. | 406,2 Mio. | 200,2 Mio. | 241,6 Mio. | 28,7 % | -40,1% | |
| All Other Countries Other Than Russia Brazil And United States | 168,4 Mio. | – | – | – | – | 20,5 % | Neu | |
| RU | 100,4 Mio. | – | – | – | – | 12,2 % | Neu | |
| BR | 65,7 Mio. | – | – | – | – | 8,0 % | Neu |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 07.05.2026 | 272,6 Mio. USD | -0,03 |
| Q3 2025 | 30.09.2025 | 04.11.2025 | 211,0 Mio. USD | 0,20 |
| Q2 2025 | 30.06.2025 | 07.08.2025 | 178,9 Mio. USD | -0,83 |
| Q1 2025 | 31.03.2025 | 06.05.2025 | 1,2 Mrd. USD | 10,04 |
| Q3 2024 | 30.09.2024 | 07.11.2024 | 196,8 Mio. USD | -1,39 |
| Q2 2024 | 30.06.2024 | 08.08.2024 | 186,7 Mio. USD | -1,29 |
| Q1 2024 | 31.03.2024 | 25.04.2024 | 210,1 Mio. USD | -1,20 |
| Q3 2023 | 30.09.2023 | 26.10.2023 | 196,6 Mio. USD | -1,76 |
| Q2 2023 | 30.06.2023 | 03.08.2023 | 213,8 Mio. USD | -2,66 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 07.05.2026 | 10-Q | 31.03.2026 | 37 Tage | SEC » |
| 19.02.2026 | 10-K | 31.12.2025 | 50 Tage | SEC » |
| 04.11.2025 | 10-Q | 30.09.2025 | 35 Tage | SEC » |
| 07.08.2025 | 10-Q | 30.06.2025 | 38 Tage | SEC » |
| 06.05.2025 | 10-Q | 31.03.2025 | 36 Tage | SEC » |
| 27.02.2025 | 10-K | 31.12.2024 | 58 Tage | SEC » |
| 07.11.2024 | 10-Q | 30.09.2024 | 38 Tage | SEC » |
| 08.08.2024 | 10-Q | 30.06.2024 | 39 Tage | SEC » |
| 25.04.2024 | 10-Q | 31.03.2024 | 25 Tage | SEC » |
| 29.02.2024 | 10-K | 31.12.2023 | 60 Tage | SEC » |
| 26.10.2023 | 10-Q | 30.09.2023 | 26 Tage | SEC » |
| 03.08.2023 | 10-Q | 30.06.2023 | 34 Tage | SEC » |
| 27.04.2023 | 10-Q | 31.03.2023 | 27 Tage | SEC » |
| 08.03.2023 | 10-K/A | 31.12.2022 | 67 Tage | SEC » |
| 21.02.2023 | 10-K | 31.12.2022 | 52 Tage | SEC » |
| 27.10.2022 | 10-Q | 30.09.2022 | 27 Tage | SEC » |
| 04.08.2022 | 10-Q | 30.06.2022 | 35 Tage | SEC » |
| 03.05.2022 | 10-Q | 31.03.2022 | 33 Tage | SEC » |
| 22.02.2022 | 10-K | 31.12.2021 | 53 Tage | SEC » |
| 28.10.2021 | 10-Q | 30.09.2021 | 28 Tage | SEC » |
| 29.07.2021 | 10-Q | 30.06.2021 | 29 Tage | SEC » |
| 04.05.2021 | 10-Q | 31.03.2021 | 34 Tage | SEC » |
| 25.02.2021 | 10-K | 31.12.2020 | 56 Tage | SEC » |
| 29.10.2020 | 10-Q | 30.09.2020 | 29 Tage | SEC » |
| 05.08.2020 | 10-Q | 30.06.2020 | 36 Tage | SEC » |
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 20.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 20.04.2026 | HV-Einladung | 02.06.2026 Jahres-HV | 10.04.2026 | DEF 14A | SEC » |
| 30.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 30.04.2025 | HV-Einladung | 17.06.2025 Jahres-HV | 21.04.2025 | DEF 14A | SEC » |
| 26.04.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 26.04.2024 | HV-Einladung | 18.06.2024 Jahres-HV | 22.04.2024 | DEF 14A | SEC » |
| 26.04.2023 | HV-Einladung | — | — | DEFA14A | SEC » |
| 26.04.2023 | HV-Einladung | 06.06.2023 Jahres-HV | 13.04.2023 | DEF 14A | SEC » |
| 28.04.2022 | HV-Einladung | — | — | DEFA14A | SEC » |
| 28.04.2022 | HV-Einladung | 08.06.2022 Jahres-HV | 14.04.2022 | DEF 14A | SEC » |
| 15.04.2022 | Vorläufig | — | — | PRE 14A | SEC » |
| 29.04.2021 | HV-Einladung | — | — | DEFA14A | SEC » |
| 29.04.2021 | HV-Einladung | 08.06.2021 Jahres-HV | 16.04.2021 | DEF 14A | SEC » |
| 16.04.2021 | Vorläufig | — | — | PRE 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Privatplatzierungen (Reg D)
Reg-D-Privatplatzierungen (Form D) der letzten sechs Jahre — SEC-befreite Kapitalaufnahmen ohne öffentliches Prospekt (z. B. PIPEs, Wandelanleihen an ausgewählte Investoren). Wiederholte Privatplatzierungen können auf laufenden Kapitalbedarf und Verwässerung der Altaktionäre hindeuten.
| Datum (US) | Art | Form | |
|---|---|---|---|
| 08.05.2023 | Privatplatzierung | D | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Nur Metadaten — Emissions-Betrag und Investoren stehen im Dokument (SEC-Link).
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 17.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 23.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | with, the reduction in workforce. Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 18.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors… |
| 24.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 06.12.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 09.06.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 09.06.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 16.03.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 18.06.2026 | Finanzierung/Anleihe | 0,25 | 72 | PTC Therapeutics emittiert neue Convertible Notes im Umfang von ca. $328,8 Millionen und nutzt die Nettoerlöse teilweise zum Rückkauf von be… 🔒 | SEC |
| 07.05.2026 | Quartalszahlen | 0,00 | 65 | PTC Therapeutics kündigt Konferenzanruf für 7. Mai 2026, 16:30 Uhr ET zur Präsentation der Finanzergebnisse Q1 2026 (bis 31. März 2026) und … 🔒 | SEC |
| 28.04.2026 | Sonstiges | 0,80 | 80 | PTC Therapeutics berichtete positive Topline-Ergebnisse aus der 24-Monats-Zwischenanalyse der PIVOT-HD Langzeitverlängerungsstudie für Votop… 🔒 | SEC |
| 25.03.2026 | Personalwechsel | 0,10 | 40 | PTC Therapeutics kündigte am 25.03.2026 die Ernennung von Ms. Chutter an; Details in beigefügter Pressemitteilung. | SEC |
| 19.02.2026 | Quartalszahlen | 0,10 | 40 | PTC Therapeutics kündigt Konferenzanruf am 19. Februar 2026 an, in dem Finanzergebnisse für Q4 2025 und das Geschäftsjahr 2025 sowie Unterne… 🔒 | SEC |
| 12.02.2026 | Sonstiges | 0,00 | 5 | Item 7.01 enthält nur Standard-Disclaimer zu Reg FD Disclosure ohne substanzielle Unternehmensmitteilung oder Ereignis. | SEC |
| 12.01.2026 | Quartalszahlen | 0,00 | 50 | PTC Therapeutics veröffentlicht Geschäftsergebnisse mit Offenlegung nicht-GAAP angepasster R&D- und SG&A-Ausgaben (exklusive aktienbasierter… 🔒 | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 124.368 | 81,57 | 10.144.698 |
| 2026-06-26 | 11 | 84,51 | 930 |
| 2026-06-22 | 10 | 78,98 | 790 |
| 2026-06-17 | 7.985 | 73,27 | 585.061 |
| 2026-06-12 | 7 | 74,71 | 523 |
| 2026-06-04 | 1.281 | 68,68 | 87.979 |
| 2026-06-01 | 2.392 | 73,85 | 176.649 |
| 2026-05-26 | 745 | 68,81 | 51.263 |
| 2026-05-22 | 7 | 69,79 | 489 |
| 2026-05-20 | 864 | 70,31 | 60.748 |
| 2026-05-14 | 7 | 73,46 | 514 |
| 2026-05-08 | 11.393 | 64,49 | 734.735 |
| 2026-05-06 | 235 | 65,04 | 15.284 |
| 2026-04-29 | 71 | 70,26 | 4.988 |
| 2026-04-27 | 7 | 68,23 | 478 |
| 2026-04-21 | 2.218 | 72,32 | 160.406 |
| 2026-04-20 | 42 | 72,43 | 3.042 |
| 2026-04-13 | 1.900 | 68,69 | 130.511 |
| 2026-04-09 | 48.960 | 71,26 | 3.488.890 |
| 2026-04-02 | 24 | 68,75 | 1.650 |
| 2026-04-01 | 24 | 68,13 | 1.635 |
| 2026-03-30 | 90 | 66,13 | 5.952 |
| 2026-03-27 | 106 | 67,00 | 7.102 |
| 2026-03-25 | 1.751 | 64,54 | 113.010 |
| 2026-03-23 | 1.598 | 65,30 | 104.349 |
| 2026-03-19 | 259 | 67,00 | 17.353 |
| 2026-03-17 | 9 | 66,71 | 600 |
| 2026-03-13 | 65 | 63,36 | 4.118 |
| 2026-03-09 | 49 | 62,82 | 3.078 |
| 2026-03-03 | 5 | 66,37 | 332 |
| 2026-02-19 | 6 | 68,93 | 414 |
| 2026-02-18 | 6 | 69,17 | 415 |
| 2026-02-11 | 5 | 72,14 | 361 |
| 2026-02-09 | 24.324 | 74,68 | 1.816.516 |
| 2026-02-06 | 19.138 | 72,36 | 1.384.826 |
| 2026-02-05 | 10.506 | 73,91 | 776.498 |
| 2026-01-30 | 3.732 | 76,43 | 285.237 |
| 2026-01-23 | 2.312 | 76,17 | 176.105 |